Company PeptiDream Inc.

Equities

4587

JP3836750004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for PeptiDream Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-10 am EDT			5-day change	1st Jan Change
2,100 ^JPY	+0.62%		+6.65%	+41.27%

Jun. 04	National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	CI
May. 14	Peptidream Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	CI

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Number of employees: 603

JPY in Million	2022	Weight	2023	Weight	Delta
Radioactive Pharmaceutical 55.8 %	11,446	42.6 %	16,009	55.8 %	+39.86%
Drug Discovery 44.2 %	15,406	57.4 %	12,703	44.2 %	-17.55%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 66.1 %	11,386	42.4 %	18,979	66.1 %	+66.68%
United States 27.7 %	13,813	51.4 %	7,952	27.7 %	-42.43%
Europe 5.1 %	1,442	5.4 %	1,472	5.1 %	+2.05%
Others 1.1 %	211	0.8 %	309	1.1 %	+46.45%

Managers	Title	Age	Since
Patrick Reid CEO	Chief Executive Officer	49	06-12-31
Kiyofumi Kaneshiro DFI	Director of Finance/CFO	46	17-12-31
Keiichi Masuya COO	Chief Operating Officer	55	14-06-30
Yuko Okimoto IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Patrick Reid CEO	Chief Executive Officer	49	06-12-31
Michio Sasaoka BRD	Director/Board Member	74	12-04-30
Junko Morita BRD	Director/Board Member	53	21-02-28
Toshio Nagae BRD	Director/Board Member	80	15-08-31
Keiichi Masuya COO	Chief Operating Officer	55	14-06-30
Yukinori Hanafusa BRD	Director/Board Member	49	17-08-31
Kiyofumi Kaneshiro DFI	Director of Finance/CFO	46	17-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	130,010,400	96,111,753 ( 73.93 %)	402,685 ( 0.3097 %)	73.93 %

Name	Equities	%	Valuation
Kiichi Kubota 9.989 %	12,987,000	9.989 %	163 M ¥
Hiroaki Suga 9.185 %	11,942,000	9.185 %	150 M ¥
M&G Investment Management Ltd. 7.536 %	9,797,900	7.536 %	123 M ¥
Taiyo Pacific Partners LP 5.063 %	6,583,000	5.063 %	82 M ¥
Hiroshi Murakami 3.367 %	4,377,000	3.367 %	55 M ¥
Patrick Reid 3.223 %	4,190,000	3.223 %	52 M ¥
Nikko Asset Management Co., Ltd. 1.386 %	1,801,700	1.386 %	23 M ¥
Alma Capital Investment Management SA (UK) 1.048 %	1,362,100	1.048 %	17 M ¥
Schroder Investment Management (Japan) Ltd. 0.6349 %	825,500	0.6349 %	10 M ¥
Sumitomo Mitsui Trust Asset Management Co., Ltd. 0.3453 %	448,900	0.3453 %	6 M ¥

Name	Equities	%	Valuation
PEPTIDREAM INC. 0.00%	200	0.00%	2,506 $

Peptidream, Inc.

3-25-23 Tonomachi Kawasaki-Ku

210-0821, Kawasaki

http://www.peptidream.com

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,100 JPY

Average target price

2,850 JPY

Spread / Average Target

+35.71%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTIDREAM INC.	+41.27%	1.73B
VERTEX PHARMACEUTICALS INCORPORATED	+18.86%	125B
REGENERON PHARMACEUTICALS, INC.	+13.73%	108B
BIONTECH SE	-7.47%	24.21B
ARGENX SE	+2.07%	22.78B
GENMAB A/S	-10.79%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-14.21%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.25%	13.58B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.66B

Bio Therapeutic Drugs